🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Yichang
Clinical trial register · China

Clinical Trials in Yichang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
State Key Laboratory of Subhealth Intervention Technology2 Yunhe Pharmaceutical (Tianjin) Co., Ltd2 BeOne Medicines2 Huashan Hospital1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Yichang

27 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
NCT07812597Obesity
DrugsZovaglutide·Semaglutide
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
210
Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde
2026-10-12
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
DrugTQF3250
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Recruiting
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
NCT07741448UTUC
DrugsTrastuzumab Rezetecan·Gemcitabine
Zhiquan Hu
Phase 2
54
Huanggang, Jingzhou, Shiyan, Wuhan, Xiangyang, Yichang
2026-08-15
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
Boehringer Ingelheim
Phase 2
342
Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang
2026-06-30
Recruiting
Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases
NCT07595068Atrial Fibrillation (AF), Cardiovascular Diseases
Renmin Hospital of Wuhan University
Not applicable
200
Huangshi, Jingzhou, Wuhan, Xiangyang, Yichang
2026-05-20
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Vitamin D Status and Multi-Omics Profiles in Primary Osteoporosis
NCT07296471Primary Osteoporosis
Dr. Li Chen
Observational
120
Yichang
2025-11-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
NCT07169331Waldenström's Macroglobulinemia
DrugZanubrutinib
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Burst Stimulation for Paroxysmal Atrial Fibrillation
NCT07281898Paroxysmal Atrial Fibrillation
Zhibing Lu
Not applicable
240
Wuhan, Xiangyang, Yichang
2025-10-13
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsBirelentinib·Venetoclax
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554Chronic Obstructive Pulmonary Disease (COPD)
DrugBBT002
Bambusa Therapeutics
Phase 1
68
Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang
2025-09-05
Not yet open
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China
NCT07075029Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese Primary Health Care Settings: Study Protocol for a Prospective Cluster Randomized Controlled Trial
NCT06963606Tuberculosis (TB)
Xuelin Yang
Not applicable
22,000
Yichang
2025-09-01
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639Tuberculosis
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Not yet open
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929Prostate Cancer Recurrent
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
DrugsEribulin·Apatinib·Camrelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Not yet open
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
NCT06633783Obesity
DrugSemaglutide
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Phase 3
370
Xuancheng, Huizhou, Luoyang, Nanyang, Zhengzhou, Yichang, Huaian, Lianyungang
2024-10-30
Recruiting
Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
NCT05604638Acute Ischemic Stroke
Second Affiliated Hospital of Guangxi Medical University
Phase 3
348
Chuzhou, Longyan, Nanning, Huanggang, Yichang, Huaihua, Shaoyang, Xiangtan
2024-04-24
Recruiting
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
NCT06467500Non-small Cell Lung Cancer
DrugCadonilimab
Xin-Hua Xu
Phase 2
48
Yichang
2024-03-01
Recruiting
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06345365Acute Myeloid Leukaemia
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Recruiting
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
NCT05439226Type 2 Diabetes
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-07-05
Recruiting
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
NCT07083336Type 2 Diabetes Mellitus, Metabolic Dysfunction-associated Steatotic Liver Disease
State Key Laboratory of Subhealth Intervention Technology
Not applicable
120
Yichang, Changsha
2022-06-05
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsIbrutinib·Pirtobrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Research on the Mechanism Affecting Progression of Bronchiectasis
NCT05731427Bronchiectasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
150
Guiyang, Wuhan, Yichang
2021-02-01
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/yichang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies with a site in Yichang.

How many clinical trials are recruiting in Yichang?

19 of the 27 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Yichang), 27 studies
PhaseStudiesRecruitingShare
Phase 38429.6%
Not applicable5518.5%
Phase 25318.5%
Observational4314.8%
Phase 13311.1%
Phase 1/2113.7%
Phase 4103.7%

Most active sponsors

Lead sponsors with the most studies (Yichang)
Lead sponsorStudiesRecruiting
BeOne Medicines22
State Key Laboratory of Subhealth Intervention Technology22
Yunhe Pharmaceutical (Tianjin) Co., Ltd20
Bambusa Therapeutics11
BeiGene10
Beijing QL Biopharmaceutical Co.,Ltd10
Boehringer Ingelheim10
Chengdu CoenBiotech Co., Ltd11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11
Dizal Pharmaceuticals11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.